$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000151655124000055 Filed on May 10, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.327M	$4.206M	$1.915M
YoY Change	258.65%	119.59%	18.05%
% of Gross Profit
Research & Development	$4.079M	$1.946M	$1.185M
YoY Change	128.06%	64.27%	-6.38%
% of Gross Profit
Depreciation & Amortization	$29.79K	$27.56K	$33.17K
YoY Change	-12.18%	-16.92%	22.97%
% of Gross Profit
Operating Expenses	$8.406M	$6.152M	$3.100M
YoY Change	195.66%	98.45%	7.35%
Operating Profit	-$8.406M	-$6.152M	-$3.100M
YoY Change	195.66%	98.45%	7.35%
Interest Expense	$510.8K	$436.9K	$18.40K
YoY Change	174.01%	2274.78%	-90.76%
% of Operating Profit
Other Income/Expense, Net	$510.8K	$1.135M	-$2.067M
YoY Change	-292.84%	-154.89%	1230.54%
Pretax Income	-$7.895M	-$5.018M	-$5.168M
YoY Change	154.02%	-2.9%	69.79%
Income Tax	$8.071K	$2.000K	$0.00
% Of Pretax Income
Net Earnings	-$7.903M	-$5.020M	-$5.168M
YoY Change	153.99%	-2.86%	69.79%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.20	-$0.18	-$0.01
Diluted Earnings Per Share	-$0.20	-$0.18	-$0.01
COMMON SHARES
Basic Shares Outstanding	28.07M shares	28.06M shares	971.5M shares
Diluted Shares Outstanding	38.67M shares	28.00M shares	941.9M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.28M	$84.16M	$2.669M
YoY Change	9020.53%	3053.49%	-55.57%
Cash & Equivalents	$74.12M	$83.34M	$2.669M
Short-Term Investments
Other Short-Term Assets	$2.707M	$1.506M	$820.0K
YoY Change	154.42%	83.71%	647.16%
Inventory
Prepaid Expenses	$1.096M	$640.5K	$957.6K
Receivables
Other Receivables
Total Short-Term Assets	$87.00M	$94.57M	$4.451M
YoY Change	4496.88%	2024.75%	-36.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.77K	$36.08K	$77.08K
YoY Change	-28.92%	-53.2%	-4.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.309K	$8.309K	$8.309K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$257.1K	$265.2K	$136.0K
YoY Change	-25.11%	94.93%	-37.6%
TOTAL ASSETS
Total Short-Term Assets	$87.00M	$94.57M	$4.451M
Total Long-Term Assets	$257.1K	$265.2K	$136.0K
Total Assets	$87.26M	$94.84M	$4.587M
YoY Change	3802.67%	1967.51%	-36.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.079M	$1.095M	$1.224M
YoY Change	-30.42%	-10.54%	39.3%
Accrued Expenses	$2.140M	$3.795M	$1.153M
YoY Change	30.43%	229.05%	113.33%
Deferred Revenue
YoY Change
Short-Term Debt	$4.860M	$4.609M	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$14.32M	$15.80M	$9.367M
YoY Change	45.9%	68.68%	124.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$129.9K	$151.0K
YoY Change	-37.72%
Total Long-Term Liabilities	$129.9K	$151.0K	$0.00
YoY Change	-37.72%		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.32M	$15.80M	$9.367M
Total Long-Term Liabilities	$129.9K	$151.0K	$0.00
Total Liabilities	$14.45M	$15.95M	$9.367M
YoY Change	44.16%	70.29%	121.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$117.3M	-$109.4M	-$71.91M
YoY Change	56.37%	52.15%	42.95%
Common Stock	$190.1M	$188.3M	$67.12M
YoY Change	182.79%	180.5%	26.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.81M	$78.88M	-$4.781M
YoY Change
Total Liabilities & Shareholders Equity	$87.26M	$94.84M	$4.587M
YoY Change	3802.67%	1967.51%	-36.39%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$7.903M	-$5.020M	-$5.168M
YoY Change	153.99%	-2.86%	69.79%
Depreciation, Depletion And Amortization	$29.79K	$27.56K	$33.17K
YoY Change	-12.18%	-16.92%	22.97%
Cash From Operating Activities	-$7.094M	-$4.708M	-$4.061M
YoY Change	256.13%	15.94%	39.32%
INVESTING ACTIVITIES
Capital Expenditures	$32.46K	$3.181K	$1.860K
YoY Change		71.02%	-6.95%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.145M	$5.532M
YoY Change		-79.3%
Cash From Investing Activities	-$32.46K	$1.142M	$5.530M
YoY Change		-79.35%	-276758.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.096M	$85.65M	-$45.31K
YoY Change	1598.45%	-189149.41%	-23.55%
NET CHANGE
Cash From Operating Activities	-7.094M	-$4.708M	-$4.061M
Cash From Investing Activities	-32.46K	$1.142M	$5.530M
Cash From Financing Activities	-2.096M	$85.65M	-$45.31K
Net Change In Cash	-9.222M	$82.09M	$1.424M
YoY Change	335.98%	5663.79%	-147.85%
FREE CASH FLOW
Cash From Operating Activities	-$7.094M	-$4.708M	-$4.061M
Capital Expenditures	$32.46K	$3.181K	$1.860K
Free Cash Flow	-$7.126M	-$4.711M	-$4.063M
YoY Change	257.76%	15.96%	39.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-307086	usd
CY2023Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1383285	usd
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.004
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4205800	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1915278	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	6152250	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	3100158	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6152250	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3100158	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	436936	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	18396	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	426514	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	24514	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1145141	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-307086	usd
CY2024Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
CY2023Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1383285	usd
CY2024Q1	skye	Wind Down Costs WindDownCosts	0	usd
CY2023Q1	skye	Wind Down Costs WindDownCosts	383109	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1134719	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2067362	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5017531	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5167520	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5019531	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5167520	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27999901	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3767578	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27999901	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3767578	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5019531	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5167520	usd
CY2024Q1	us-gaap	Depreciation Depreciation	27560	usd
CY2023Q1	us-gaap	Depreciation Depreciation	33174	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2478179	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	5141	usd
CY2024Q1	skye	Accrued Financing Charges AccruedFinancingCharges	2096054	usd
CY2023Q1	skye	Accrued Financing Charges AccruedFinancingCharges	0	usd
CY2024Q1	skye	Common Stock Warrant Exercises CommonStockWarrantExercises	0	usd
CY2023Q1	skye	Common Stock Warrant Exercises CommonStockWarrantExercises	282905	usd
CY2024Q1	skye	Conversion Of Multi Draw Credit Agreement ConversionOfMultiDrawCreditAgreement	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	131579	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	237205	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1145141	usd
CY2024Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
CY2024Q1	skye	Accrued Interest Conversion Expense AccruedInterestConversionExpense	0	usd
CY2023Q1	skye	Accrued Interest Conversion Expense AccruedInterestConversionExpense	15952	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	45351	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	446277	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-96668	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	386513	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	258443	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-60652	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-445903	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-20331	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-534919	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	134767	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16780	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	2618	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	85042	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-132654	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-95850	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4708123	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4060923	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1145141	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5532266	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3181	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1860	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1141960	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5530406	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4338393	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	85652617	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2024Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	45307	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85652617	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-45307	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82086454	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1424176	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10336655	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1249107	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92423109	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2673283	usd
CY2024Q1	us-gaap	Cash Cash	83342907	usd
CY2023Q1	us-gaap	Cash Cash	2668697	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9080202	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4586	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92423109	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2673283	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	126027	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	4275	usd
CY2023Q1	skye	Conversion Of Multi Draw Credit Agreement ConversionOfMultiDrawCreditAgreement	1565470	usd
CY2024Q1	skye	Conversion Of Accrued Interest Due To Related Party ConversionOfAccruedInterestDueToRelatedParty	0	usd
CY2023Q1	skye	Conversion Of Accrued Interest Due To Related Party ConversionOfAccruedInterestDueToRelatedParty	31766	usd
CY2024Q1	skye	Financing Of Insurance Premium FinancingOfInsurancePremium	0	usd
CY2023Q1	skye	Financing Of Insurance Premium FinancingOfInsurancePremium	203884	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2131818	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2478179	usd
CY2024Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	6434447	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	83556563	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-5019531	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78883393	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3008054	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	131579	usd
CY2023Q1	skye	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	282905	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2980521	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5167520	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4780569	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segments
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segments
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1145141	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-307086	usd
CY2024Q1	skye	Prepaid Clinical Expenses PrepaidClinicalExpenses	86940	usd
CY2023Q4	skye	Prepaid Clinical Expenses PrepaidClinicalExpenses	61352	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	553596	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	132907	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	640536	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	194259	usd
CY2024Q1	skye	Tax Rebate Current TaxRebateCurrent	525707	usd
CY2023Q4	skye	Tax Rebate Current TaxRebateCurrent	540604	usd
CY2024Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	814195	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	403439	usd
CY2024Q1	skye	Excise Tax Bonds Current ExciseTaxBondsCurrent	123051	usd
CY2023Q4	skye	Excise Tax Bonds Current ExciseTaxBondsCurrent	125784	usd
CY2024Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	26228	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	32458	usd
CY2024Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	17261	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	17644	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1506442	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1119929	usd
CY2024Q1	skye	Accrued Placement Agent Fees AccruedPlacementAgentFees	2096054	usd
CY2023Q4	skye	Accrued Placement Agent Fees AccruedPlacementAgentFees	0	usd
CY2024Q1	skye	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	452465	usd
CY2023Q4	skye	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	467784	usd
CY2024Q1	skye	Legal Professional Fee Accrual LegalProfessionalFeeAccrual	298711	usd
CY2023Q4	skye	Legal Professional Fee Accrual LegalProfessionalFeeAccrual	258213	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	123169	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	180897	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	124586	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	69468	usd
CY2024Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	84662	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	22190	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3179647	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	998552	usd
CY2024Q1	skye	Class Of Warrant Or Right Warrants Vested And Outstanding ClassOfWarrantOrRightWarrantsVestedAndOutstanding	13259679	shares
CY2024Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	10155039	usd
CY2024Q1	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	124658	usd
CY2023Q1	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	15952	usd
CY2024Q1	skye	Legal Fees Interest Expense LegalFeesInterestExpense	75073	usd
CY2023Q1	skye	Legal Fees Interest Expense LegalFeesInterestExpense	0	usd
CY2024Q1	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	2444	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	237205	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	436936	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	18396	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3767578	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2478179	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	131579	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14398828	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y9M
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5019531	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5019531	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5167520	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5167520	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27999901	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27999901	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3767578	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2024Q1	skye	Legal Fees Interest Expense LegalFeesInterestExpense	75073	usd
CY2024Q1	skye	Loss Contingency Net Cash Received To Cover Legal Expenses LossContingencyNetCashReceivedToCoverLegalExpenses	5000000	usd

Files In Submission

Name	View Source	Status
0001516551-24-000055-index-headers.html	Edgar Link	pending
0001516551-24-000055-index.html	Edgar Link	pending
0001516551-24-000055.txt	Edgar Link	pending
0001516551-24-000055-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skye-20240331.htm	Edgar Link	pending
skye-20240331.xsd	Edgar Link	pending
skye-20240331xex10x1.htm	Edgar Link	pending
skye-20240331xex311.htm	Edgar Link	pending
skye-20240331xex321.htm	Edgar Link	pending
skye-20240331xex322.htm	Edgar Link	pending
skye-20240332xex312.htm	Edgar Link	pending
skye-20240331_cal.xml	Edgar Link	unprocessable
skye-20240331_def.xml	Edgar Link	unprocessable
skye-20240331_lab.xml	Edgar Link	unprocessable
skye-20240331_pre.xml	Edgar Link	unprocessable
skye-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2024 Q2 Form 10-Q Financial Statement

#000151655124000055 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2024 Q2 Form 10-Q Financial Statement

#000151655124000055 Filed on May 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye